|Bid||0.00 x 1200|
|Ask||0.00 x 1400|
|Day's Range||47.80 - 48.49|
|52 Week Range||41.23 - 58.37|
|Beta (3Y Monthly)||0.94|
|PE Ratio (TTM)||19.52|
|Forward Dividend & Yield||1.27 (2.66%)|
|1y Target Est||49.41|
Diabetes and related conditions affect over 100 million Americans and many more worldwide. Here are three companies helping fight that disease.
According to the GuruFocus All-in-One Screener, the following stocks are trading at a discount and have positive three- to five-year future earnings estimates. Warning! GuruFocus has detected 5 Warning Sign with SCI. The discounted cash flow calculator gives the stock a fair value of $46.95 per share, suggesting it has an 11% margin of safety.
AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and its top line is driven by strong performance of products like Victoza.
Johnson & Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among its top-selling products. J&J joined many other companies that raised U.S. prices on hundreds of prescription medicines earlier this month. Most of the J&J increases were between 6 percent and 7 percent, according to data from Rx Savings Solutions, which helps health plans and employers seek lower cost prescription medicines.
have raised prices of insulin in the US, despite political pressure as diabetics protest and lobby lawmakers over the rising cost of the essential medicine. Sanofi increased the price of its three main insulin brands by between 4.4 per cent and 5.2 per cent last week, while Novo Nordisk increased the price of its insulin products by just under 5 per cent on Tuesday. Depending on the dose and brand, the list prices for insulin products vary between $300 and $400.
The following is an update on the 2018 performance of individual accounts I run along with the returns of the Hayashi Foundation - a not-for-profit fund based in Japan, of which I am currently chief investment officer. As many of you know, I left Dorfman Value Investments and opened my own investment firm - Nintai Investments LLC - on Oct. 1, 2018. The numbers in this report reflect a composite of fees from both Dorfman and Nintai.
Novo Nordisk (NVO) has a strong presence in the Diabetes Care market and boasts a strong pipeline, with focus on therapeutic proteins within insulin.
Heading into December, biotech stocks held up fairly well in 2018. Evaluate Pharma , a firm specializing in data-driven news and analysis in biotech, compiled a list of blockbuster drugs in the works with ...
The average American is nearing the medical definition of obesity, according to new data from the Centers for Disease Control. As many as six new drugs to combat obesity may hit the market in the coming years and improve heart health as well as provide weight-loss benefits. There are more than 97 million people with obesity in the U.S., and that number is set to increase by nearly 3 percent annually on average.
The deals include $145 million in cash and the purchase of $36.7 million in Strongbridge stock by Novo Nordisk
Billionaire hedge fund managers such as Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the big players […]
Experimental new drugs at critical stages of development could soon send these stocks screaming in one direction or another.
Under the partnership, the companies will develop a treatment for hypertriglyceridemia, or high levels of fat in the blood. Staten’s antibody is designed to neutralize apoC3, a key molecule in the management of high lipid levels in the blood, to reduce triglyceride levels, according to the company.
As pharmaceutical production continues to expand in counties east of the Triangle, Novo Nordisk has announced another $22 million expansion of its Clayton facility.
Zafgen's (ZFGN) stock plunges significantly as the FDA placed a clinical hold on the company's first trial on experimental diabetes drug, ZGN-1061.
The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources
The government requires hedge funds and wealthy investors with over a certain portfolio size to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings discloses the funds’ positions on June […]
A/S is cutting costs and reallocating research and development spending as it faces price pressures in the U.S., its biggest market. Four hundred jobs will be eliminated in the company’s research and development unit. Most of the savings in the R&D department will be reinvested in artificial intelligence, cloud services and automation technologies, Mr. Knudsen said.
Novo Nordisk (NOVOb.CO), the world's top maker of diabetes drugs, reported encouraging sales of its main growth drivers on Thursday as it announced more job cuts amid a restructuring to cope with intensifying pricing pressure in the United States. Sales of Novo's new once-weekly Ozempic GLP-1 drug, which the Danish company hopes will take market share from Eli Lilly's (LLY.N) Trulicity, beat forecasts for the third quarter. Eli Lilly has been eating into Novo's previously fast-selling Victoza - a so-called GLP-1 drug that imitates an intestinal hormone to stimulate insulin production.
Novo Nordisk, the world's top maker of diabetes drugs, reported encouraging sales of its main growth drivers on Thursday as it announced more job cuts amid a restructuring to cope with intensifying pricing pressure in the United States. Sales of Novo's new once-weekly Ozempic GLP-1 drug, which the Danish company hopes will take market share from Eli Lilly's Trulicity, beat forecasts for the third quarter. Eli Lilly has been eating into Novo's previously fast-selling Victoza - a so-called GLP-1 drug that imitates an intestinal hormone to stimulate insulin production.
On a per-share basis, the Bagsvaerd, Denmark-based company said it had net income of 58 cents. The drugmaker posted revenue of $4.31 billion in the period. Novo Nordisk shares have fallen 19 percent since ...